For research use only. Not for therapeutic Use.
Mapracorat is a selective glucocorticoid receptor agonist (SEGRA) known for its anti-inflammatory and immunosuppressive properties. Unlike traditional glucocorticoids, mapracorat is designed to reduce inflammation with fewer side effects, such as skin thinning and systemic immunosuppression. It works by modulating the glucocorticoid receptor, which influences the expression of anti-inflammatory genes and reduces the production of pro-inflammatory cytokines. Mapracorat is primarily investigated for its potential in treating inflammatory conditions like dermatitis, asthma, and ocular inflammation, offering a promising alternative to conventional corticosteroid therapies with an improved safety profile.
| Catalog Number | I007907 |
| CAS Number | 887375-26-0 |
| Synonyms | (2R)-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydro-1-benzofuran-7-yl)-4-methyl-2-[[(2-methylquinolin-5-yl)amino]methyl]pentan-2-ol |
| Molecular Formula | C25H26F4N2O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C25H26F4N2O2/c1-15-7-8-18-20(5-4-6-21(18)31-15)30-14-24(32,25(27,28)29)13-23(2,3)19-12-17(26)11-16-9-10-33-22(16)19/h4-8,11-12,30,32H,9-10,13-14H2,1-3H3/t24-/m1/s1 |
| InChIKey | VJGFOYBQOIPQFY-XMMPIXPASA-N |
| SMILES | CC1=NC2=C(C=C1)C(=CC=C2)NCC(CC(C)(C)C3=CC(=CC4=C3OCC4)F)(C(F)(F)F)O |
